Floatz logo

S-1

Liver Diseases

Second Military Medical UniversityPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Liver Diseases cohort.

Asset / SponsorPhaseRating
Pioglitazone
Yonsei University
Phase 4BBB
Empagliflozin
Military University Hospital, Prague
Phase 4BB
Hep-V Vax
University of Oxford
Phase 4BB
NEPENTHE
Anhui Provincial Hospital
Phase 4BB
DEXKETOPROFEN
Anhui Provincial Hospital
Phase 4BB

View all 39 →

Same molecule, other indications

S-1 is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Gastric NeoplasmDormant
BB
Indicative ·
69 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →